Report Highlights
The global cognition and memory-enhancing drugs market should reach over $4.2 billion by 2022 from $2.8 billion in 2017 at a compound annual growth rate (CAGR) of 8.7% for the period 2017-2022.
Report Includes
- 34 data tables and 14 additional tables
- An overview of the global market for cognition and memory enhancement drugs
- Analyses of global market trends, with data from 2016 to 2017, and projections of compound annual growth rates (CAGRs) through 2022
- An overview of the ethics and side effects of cognition and memory enhancement drugs
- Market analyses by application, product, and region
- Assessment of patent litigation claims
- Insight into the competitive landscape, including mergers and acquisitions and new product launches
- Profiles of key companies in the market, including Pfizer, Novartis, Shire Pharmaceuticals, Allergan Plc, Barr Pharmaceuticals, and Cephalon
Report Scope
This research report presents an in-depth analysis of the global cognition and memory-enhancing drugs market by application, product categories, and regional markets. The report includes key cognition drugs that are incorporated in several therapeutic treatment methods. It discusses the role of supply chain members from manufacturers to researchers. The report has an in-depth analysis of key companies operating in the global cognition and memory-enhancing drugs market. In-depth patent analysis in the report will focus on providing extensive technological trends across years and regions such as the U.S., Europe, and China.
The cognition and memory-enhancing drugs market is segmented mainly into eight components: Aricept, Exelon, Reminyl, Namenda, Adderall, Ritalin, Dexedrin, and other cognition drugs. This market is further segmented on the basis of applications, which helps in understanding the potency of these memory enhancers in several therapeutic treatments. The market study is detailed for products based on applications as well as its further implication on the research and development area. These two segmentations are also discussed in detail for the given period. The market is segmented by region into the North America, Europe, Asia-Pacific, and ROW. Companies profiled in this report include Pfizer, Novartis, Shire Pharmaceuticals, Allergan plc, Barr Pharmaceuticals, and Cephalon.
Analyst Credentials
Sangeeta Rai is a senior researcher who has analyzed and forecasted healthcare and advanced chemicals markets since 2011. She holds a Bachelor of Science in biotechnology and a Master of Business Administration in marketing. Prior to joining BCC Research, she has held senior research roles at Global Data and Infinity Research. Sangeeta Rai is a pseudonym of the author.
Related Reports
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
The global market for Alzheimer’s disease therapeutics and diagnostics was valued at $9 billion in 2023. This market is expected to grow from $9.7 billion in 2024 to $19.6 billion by 2029, at a compound annual growth rate (CAGR) of 15.1% from 2024 to 2029.
2021 Pharmaceuticals Research Review
BCC Research Market Report for generic drugs should grow from $411.6 billion in 2020 to $650.3 billion by 2025, at compound annual growth rate (CAGR) of 9.6%
Anti-Parkinson's Drugs: Global Markets to 2022
The global anti-Parkinson’s drugs market should reach $5.7 billion by 2022 from $4.2 billion in 2017 at a compound annual growth rate (CAGR) of 6.1% from 2017 to 2022.
Recent Reports
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
The global market for Alzheimer’s disease therapeutics and diagnostics was valued at $9 billion in 2023. This market is expected to grow from $9.7 billion in 2024 to $19.6 billion by 2029, at a compound annual growth rate (CAGR) of 15.1% from 2024 to 2029.
Laboratory Animal Models, 3D Cultures, and Organoids: Global Markets
The global market for laboratory animal models, 3D cultures, and organoids is estimated to increase from $2.8 billion in 2024 to reach $5.0 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.
Rare Disease Diagnostics: Technologies and Global Markets
The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.
Breakthrough Therapies: Market Dynamics and Investment Opportunities
The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.
Softgel Capsules: Global Markets
The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More